Back to search

Poland· PL-100232581

Gaviscon o smaku mięty TAB

A alginic acid product containing natrii alginas + natrii hydrogenocarbonas + calcii carbonas, registered in Poland by Reckitt Benckiser (Poland) S.A.. The same ATC class is registered in 10 of our 19 countries.

ATC A02BX13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedGaviscon o smaku mięty TABATCA02BX13REGISTER NO.PL-100232581PACKS LISTED17CHECKEDSeptember 27, 2026

Where it is registered

Alginic acid is registered in 10 of 19 countries.

Countries holding a registration under ATC A02BX13 (alginic acid), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose

Alginic acid · ATC A02BX13

10 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Natrii alginas + Natrii hydrogenocarbonas + Calcii carbonas
Manufacturer
Reckitt Benckiser (Poland) S.A.
Country
Poland (PL)
ATC code
A02BX13
ATC class
Alginic acid
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 17

  • gtin
    05909990803347
  • gtin
    05909990803354
  • gtin
    05909990803361
  • gtin
    05909990803378
  • gtin
    05909990803385
  • gtin
    05909990803392
  • gtin
    05909990803408
  • gtin
    05909990803422
  • gtin
    05909990803439
  • gtin
    05909990803446
  • gtin
    05909990803453
  • gtin
    05909990803460
  • gtin
    05909990803477
  • gtin
    05909990803484
  • gtin
    05909990803491
  • gtin
    05909990803507
  • gtin
    05909990803521

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/45e34fa5-27b0-4467-bd5f-95bd88e09790
GET /v1/drugs/45e34fa5-27b0-4467-bd5f-95bd88e09790?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki do rozgryzania i żucia",
  "source": "urpl",
  "strength": "250 mg + 133,5 mg + 80 mg",
  "packaging": "05909990803347 ¦ OTC ¦ 60253\n8 tabl. w blistrach\n05909990803354 ¦ OTC ¦ 60375\n16 tabl. w blistrach\n05909990803361 ¦ OTC ¦ 60376\n24 tabl. w blistrach\n05909990803378 ¦ OTC ¦ 60377\n32 tabl. w blistrach\n05909990803385 ¦ OTC ¦ 60378\n48 tabl. w blistrach\n05909990803392 ¦ OTC ¦ 60379\n8 tabl. w pojemniku\n05909990803408 ¦ OTC ¦ 60380\n12 tabl.\n05909990803422 ¦ OTC ¦ 60381\n16 tabl. w pojemniku\n05909990803439 ¦ OTC ¦ 60382\n18 tabl.\n05909990803446 ¦ OTC ¦ 60383\n20 tabl.\n05909990803453 ¦ OTC ¦ 60384\n22 tabl.\n05909990803460 ¦ OTC ¦ 60385\n24 tabl. w pojemniku\n05909990803477 ¦ OTC ¦ 60386\n32 tabl. w pojemniku\n05909990803484 ¦ OTC ¦ 60387\n36 tabl.\n05909990803491 ¦ OTC ¦ 60388\n40 tabl.\n05909990803507 ¦ OTC ¦ 60389\n44 tabl.\n05909990803521 ¦ OTC ¦ 60390\n48 tabl. w pojemniku",
  "substance": "Natrii alginas 250 mg + Natrii hydrogenocarbonas 133.5 mg + Calcii carbonas 80 mg",
  "common_name": "Natrii alginas + Natrii hydrogenocarbonas + Calcii carbonas",
  "pl_product_id": "100232581",
  "pozwolenie_nr": "17332",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}

See everything about alginic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.